Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 7/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.41 |
| ▸ | IKBKB | O14920 | 2/20 | 0.40 |
| ▸ | CHUK | O15111 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20021959 | 0.85 | BCL9 (0.40) | HRH1PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL27522110 | 0.81 | HRH1 (0.71) | HRH1PDE4ANCOA1NCOA3PDE4D | |
| SCHEMBL20021945 | 0.78 | PDE4A (0.60) | HRH1PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL21295384 | 0.77 | SLC6A4 (0.49) | HRH1PDE4ANCOA1NCOA3PDE4D | |
| SCHEMBL30744005 | 0.77 | SLC6A4 (0.49) | HRH1PDE4ANCOA1NCOA3PDE4D | |
| SCHEMBL4324881 | 0.76 | PTGDR2 (0.60) | PTGDR2NCOA1NCOA3 | |
| SCHEMBL10012300 | 0.75 | CSNK2A1 (0.45) | PDE4APDE4DPDE4BPDE4CCSNK2A1 | |
| SCHEMBL15550215 | 0.74 | BRD4 (0.46) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL24984553 | 0.74 | HRH1 (0.53) | HRH1PTGDR2IKBKBCHUKLCK | |
| SCHEMBL7227806 | 0.74 | HRH1 (0.76) | HRH1PDE4ANCOA1NCOA3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | HRH1 4791/4885PTGDR2 4637/4885PDE4A 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.